D-Cycloserine acts as inhibitor of various enzymes.[1]
Biochem/physiol Actions
Mode of Action: Inhibits cell wall biosynthesis (D-Ala peptide bond formation). Also prevents conversion of D-Ala to L-Ala. Bacteriostatic. Partial agonist at the glycine modulatory site of NMDA glutamatergic receptors; antibiotic against Gram-negative bacteria. Mode of Resistance: D-Ala transport interference.
Mode of Action: Inhibits cell wall biosynthesis (D-Ala peptide bond formation). Also prevents conversion of D-Ala to L-Ala. Bacteriostatic. Mode of Resistance: D-Ala transport interference.
Packaging
1g, 5g, 25g
Other Notes
Keep container tightly closed in a dry and well-ventilated place. Store under inert gas. Air sensitive. Keep in a dry place.
Depression and anxiety, 32(6), 408-414 (2015-03-17)
For exposure therapy to be successful, it is essential that fear extinction learning extends beyond the treatment setting. D-cycloserine (DCS) may facilitate treatment gains by increasing generalization of extinction learning, however, its effects have not been tested in children. We
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 24(11), 1798-1807 (2014-12-03)
Previous research has demonstrated that systemic D-cycloserine (DCS), a partial agonist of the N-methyl-D-aspartate receptor (NMDAR), enhances memory processes in different learning paradigms and attenuates mnemonic deficits produced by diverse pharmacological manipulations. In the present study two experiments were conducted
Current psychiatry reports, 17(1), 532-532 (2014-11-22)
Although cognitive behavioral therapy (CBT) is a generally effective treatment for treating anxiety disorders, there is clearly still room for further improvements. Recent advances in neuroscience of extinction learning led to novel clinical strategies to augment exposure-based treatments with d-cycloserine
Current psychiatry reviews, 10(4), 317-324 (2014-11-11)
Variants of exposure therapy are effective for treating obsessive-compulsive and related disorders (OCRDs). However, significant numbers of patients do not respond adequately to exposure therapy resulting in continued distress and functional impairment. Therefore, novel approaches to augmenting exposure therapy are
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
